Beximco Pharmagdr Regs Stock Gross Profit
| R2WA Stock | EUR 0.41 0.00 0.00% |
BEXIMCO PHARMAGDR REGS fundamentals help investors to digest information that contributes to BEXIMCO PHARMAGDR's financial success or failures. It also enables traders to predict the movement of BEXIMCO Stock. The fundamental analysis module provides a way to measure BEXIMCO PHARMAGDR's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BEXIMCO PHARMAGDR stock.
BEXIMCO |
BEXIMCO PHARMAGDR REGS Company Gross Profit Analysis
BEXIMCO PHARMAGDR's Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Current BEXIMCO PHARMAGDR Gross Profit | 15.71 B |
Most of BEXIMCO PHARMAGDR's fundamental indicators, such as Gross Profit, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BEXIMCO PHARMAGDR REGS is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
| Competition |
According to the company disclosure, BEXIMCO PHARMAGDR REGS reported 15.71 B of gross profit. This is much higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers-Specialty & Generic industry. The gross profit for all Germany stocks is 42.6% higher than that of the company.
BEXIMCO Gross Profit Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BEXIMCO PHARMAGDR's direct or indirect competition against its Gross Profit to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BEXIMCO PHARMAGDR could also be used in its relative valuation, which is a method of valuing BEXIMCO PHARMAGDR by comparing valuation metrics of similar companies.BEXIMCO PHARMAGDR is currently regarded as top stock in gross profit category among its peers.
BEXIMCO Fundamentals
| Return On Equity | 0.12 | |||
| Return On Asset | 0.0659 | |||
| Profit Margin | 0.14 % | |||
| Shares Outstanding | 446.11 M | |||
| Shares Owned By Institutions | 2.09 % | |||
| Gross Profit | 15.71 B | |||
| Debt To Equity | 27.50 % | |||
| Current Ratio | 2.26 X | |||
| Earnings Per Share | 0.10 X | |||
| Number Of Employees | 5.5 K | |||
| Beta | 0.8 | |||
| Market Capitalization | 563.15 M | |||
| Annual Yield | 0.06 % |
About BEXIMCO PHARMAGDR Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BEXIMCO PHARMAGDR REGS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BEXIMCO PHARMAGDR using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BEXIMCO PHARMAGDR REGS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in BEXIMCO Stock
BEXIMCO PHARMAGDR financial ratios help investors to determine whether BEXIMCO Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BEXIMCO with respect to the benefits of owning BEXIMCO PHARMAGDR security.